Abivax (NASDAQ:ABVX) Given “Buy” Rating at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Abivax (NASDAQ:ABVX) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $150.00 price objective on the stock.

A number of other brokerages have also weighed in on ABVX. Wolfe Research upgraded Abivax to a “strong-buy” rating in a research note on Thursday, November 6th. Citigroup reissued a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Oppenheimer set a $131.00 price objective on shares of Abivax in a research note on Thursday, January 8th. Finally, Morgan Stanley boosted their target price on shares of Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Abivax currently has an average rating of “Moderate Buy” and a consensus target price of $134.75.

Abivax Price Performance

ABVX opened at $123.33 on Wednesday. Abivax has a twelve month low of $4.77 and a twelve month high of $148.83. The firm has a market cap of $9.75 billion, a price-to-earnings ratio of -29.50 and a beta of 0.79. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The company has a fifty day simple moving average of $124.05 and a 200 day simple moving average of $105.37.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million for the quarter. Equities research analysts expect that Abivax will post -2.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Kennedy Capital Management LLC raised its position in shares of Abivax by 7.1% during the 2nd quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after purchasing an additional 15,997 shares during the period. Federated Hermes Inc. acquired a new position in Abivax during the 3rd quarter worth $8,448,000. Persistent Asset Partners Ltd bought a new position in Abivax in the 3rd quarter valued at about $815,000. Privium Fund Management B.V. bought a new position in shares of Abivax in the third quarter valued at approximately $2,582,000. Finally, Simplify Asset Management Inc. acquired a new position in shares of Abivax during the 3rd quarter valued at $5,217,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.